Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

References

• Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(2):ii30–6. doi:10.1136/ard.2004.031120
   PubMedGoogle Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26. doi:10.1038/jid.2012.194
   PubMed Web of Science ®Google Scholar
• Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S2–6.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32(1):227–255. doi:10.1146/annurev-immunol-032713-120225
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Karason A, Antonsdottir AA, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol. 2002;118(2):362–365. doi:10.1046/j.0022-202x.2001.01656.x
   PubMed Web of Science ®Google Scholar
• Burlando M, Russo R, Clapasson A, et al. The HLA-Cw6 Dilemma: is it really an outcome predictor in psoriasis patients under biologic therapy? A monocentric retrospective analysis. J Clin Med. 2020;9(10):3140. doi:10.3390/jcm9103140
   PubMed Web of Science ®Google Scholar
• Liu X, DePrimo S, Chen Y, Li S, Munoz-Elias E. 451 Association between HLA-Cw6 status and response to guselkumab in patients with moderate to severe plaque psoriasis. Int Invest Dermatol. 2018;138(5):S76.
   Web of Science ®Google Scholar
• Li K, Huang CC, Randazzo B, et al. HLA-C*06:02 allele and response to il-12/23 inhibition: results from the ustekinumab phase 3 psoriasis program. J Invest Dermatol. 2016;136(12):2364–2371. doi:10.1016/j.jid.2016.06.631
   PubMed Web of Science ®Google Scholar
• Temel B, Adisen E, Gonen S. HLA-Cw6 status and treatment responses between psoriasis patients. Indian J Dermatol. 2021;66(6):632–637. doi:10.4103/ijd.IJD_282_21
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, van den Reek J, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34(1):112–118. doi:10.1111/jdv.15787
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi:10.1016/j.jaad.2015.05.013
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146. doi:10.1016/S0140-6736(15)61134-5
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Schakel K, Hong CH, et al. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. J Dermatol Treat. 2021;32(1):1–9. doi:10.1080/09546634.2021.1902925
   PubMedGoogle Scholar
• Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179(5):1072–1080. doi:10.1111/bjd.16705
   PubMed Web of Science ®Google Scholar
• Papini M, Cusano F, Romanelli M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol. 2019;181(2):413–414. doi:10.1111/bjd.18013
   PubMed Web of Science ®Google Scholar
• Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273–275. doi:10.1016/j.jaad.2019.02.031
   PubMed Web of Science ®Google Scholar
• Lee EB, Amin M, Egeberg A, Wu JJ. Drug survival of secukinumab for psoriasis in a real-world setting. J Dermatol Treat. 2019;30(2):150–151. doi:10.1080/09546634.2018.1473838
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519. doi:10.1111/bjd.16102
   PubMed Web of Science ®Google Scholar
• Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169(2):458–463. doi:10.1111/bjd.12331
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chimenti S, Costanzo A. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol. 2016;74(2):374–375. doi:10.1016/j.jaad.2015.08.055
   PubMed Web of Science ®Google Scholar
• Coto-Segura P, Gonzalez-Lara L, Batalla A, Eiris N, Queiro R, Coto E. NFKBIZ and CW6 in adalimumab response among psoriasis patients: genetic association and alternative transcript analysis. Mol Diagn Ther. 2019;23(5):627–633. doi:10.1007/s40291-019-00409-x
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130. doi:10.1016/j.jaci.2018.11.038
   PubMed Web of Science ®Google Scholar
• Zorlu O, Bulbul Baskan E, Yazici S, et al. Predictors of drug survival of biologic therapies in psoriasis patients. J Dermatol Treat. 2022;33(1):437–442. doi:10.1080/09546634.2020.1763240
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British association of dermatologists biologics and immunomodulators register (BADBIR). Br J Dermatol. 2020;183(2):294–302. doi:10.1111/bjd.18981
   PubMed Web of Science ®Google Scholar
• Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med Lausanne. 2020;7:625755. doi:10.3389/fmed.2020.625755
   PubMed Web of Science ®Google Scholar
• Chatzimichail G, Gunther J, Stander S, Thaci D. Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. J Dermatol Treat. 2022;33(3):1749–1753. doi:10.1080/09546634.2020.1854428
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514. doi:10.1111/jdv.14878
   PubMed Web of Science ®Google Scholar